In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $387.15, denoting a -1.08% move from the preceding trading day.

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

This biotech is a leader in the treatment of cystic fibrosis, and that’s helped earnings explode higher over the years. The ...

Progress in the healthcare field is allowing us to live longer. However, as people age, their need for medical services tends to increase. Over the next few decades, the percentage of the world's ...

Vertex Pharmaceuticals Incorporated just reported a robust Q2 with earnings per share of $4.52, surpassing estimates and ...

If you have been eyeing Vertex Pharmaceuticals and wondering whether it is the right time to buy, sell, or simply hold tight, ...

CRISPR Therapeutics AG is a long-term buy despite slow Casgevy uptake. Click for my updated look at CRSP earnings and the ...

Wall Street stocks finished in a mixed fashion on Wednesday after an interest-rate cut and comments from the Federal Reserve ...